Journal List > Endocrinol Metab > v.26(2) > 1085877

Lee, Ku, Kim, Lee, Lim, Hwang, Kim, Shin, and Lee: A Case of Pituitary Adenoma with Simultaneous Secretion of TSH and GH

초록

Thyrotropin (TSH)-secreting pituitary adenoma is a very rare disease. In one-quarter of patients suffering from this disease, the pituitary tumor secretes other anterior pituitary hormones. Herein, we report a case of pituitary adenoma with simultaneous secretion of TSH and growth hormone (GH). A 34-year-old female visitied local hospital complaining of sweating, intermittent palpita-tion, and weight loss of 8 kg within 1 year. The patient had undergone trans-sphenoidal surgery 3 years prior for resolution of a TSH and GH co-secreting pituitary adenoma. She had been administered somatostatin analogue prior to visiting our hospital. The patient's GH levels were suppressed to below 1 ng/mL on the 75 g oral glucose tolerance test, and her basal insulin-like growth factor-I (IGF-I) level was within normal range. Thyroid function tests demonstrated increased levels of both free thyroxine and TSH. Sella-MRI revealed pituitary adenoma at the floor of the pituitary fossa, approximately 2 cm in height. Therefore, she was diagnosed with residual TSH-secreting pituitary adenoma. The patient again underwent trans-sphenoidal surgery and entered complete remission, based on hormone levels and MRI findings.

REFERENCES

1. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 17:610–638. 1996.
crossref
2. Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 23:597–606. 2009.
3. Jailer JW, Holub DA. Remission of Graves' disease following radiotherapy of a pituitary neoplasm. Am J Med. 28:497–500. 1960.
crossref
4. Swearingen B, Biller BMK. Diagnosis and management of pituitary disorders. 1st ed.p. 237–270. Totowa, NJ: Humana Press Inc;2008.
5. Beck-Peccoz P, Persani L. Thyrotropin-secreting pituitary adenomas. www.thyroidmanager.org/. (Date accessed May 13. 2011.
6. Hamilton CR Jr, Adams LC, Maloof F. Hyperthyroidism due to thyrotro-pin-producing pituitary chromophobe adenoma. N Engl J Med. 283:1077–1080. 1970.
crossref
7. Sanno N, Teramoto A, Osamura RY. Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neu-rooncol. 54:179–186. 2001.
8. Beck-Peccoz P, Persani L, Mantovani S, Cortelazzi D, Asteria C. Thyrotro-pin-secreting pituitary adenomas. Metabolism. 45:75–79. 1996.
crossref
9. Beckers A, Abs R, Mahler C, Vandalem JL, Pirens G, Hennen G, Steven-aert A. Thyrotropin-secreting pituitary adenomas: report of seven cases. J Clin Endocrinol Metab. 72:477–483. 1991.
crossref
10. Kim CH, Kim GS, Kim HK, Park JY, Shong YK, Hong SB, Ko JM, Kim CJ. Pituitary thyrotropin-secreting tumors in Korean. J Korean Soc Endocrinol. 12:165–175. 1997.
11. Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev. 23:431–442. 2002.
crossref
12. Mantovani G, Asteria C, Pellegrini C, Bosari S, Alberti L, Bondioni S, Pever-elli E, Spada A, Beck-Peccoz P. HESX1 expression in human normal pitu-itaries and pituitary adenomas. Mol Cell Endocrinol. 247:135–139. 2006.
crossref
13. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 84:476–486. 1999.
crossref
14. Kronenberg H, Williams RH. Williams textbook of endocrinology. 11th ed.p. 396–397. Philadelphia, Edinburgh: Saunders Elsevier;2008.
15. Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Col-andrea JM, Doppman JL, Oldfield EH, Weintraub BD. Thyrotropin-se-creting pituitary carcinoma. J Clin Endocrinol Metab. 76:529–533. 1993.
crossref
16. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Steve-naert A, Beckers A. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 148:433–442. 2003.
crossref
17. Ezzat S, Horvath E, Kovacs K, Smyth HS, Singer W, Asa SL. Basic fibro-blast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocr Pathol. 6:125–134. 1995.
crossref
18. Webster J, Peters JR, John R, Smith J, Chan V, Hall R, Scanlon MF. Pituitary stone: two cases of densely calcified thyrotrophin-secreting pituitary adenomas. Clin Endocrinol (Oxf). 40:137–143. 1994.
crossref
19. Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M. Somatostatin receptor subtypes mRNA in TSH-secret-ing pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J. 54:371–378. 2007.
crossref
20. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Crite-ria of cure and follow-up of central hyperthyroidism due to thyrotropin-se-creting pituitary adenomas. J Clin Endocrinol Metab. 81:3084–3090. 1996.
crossref

Fig. 1.
A coronal view of TSH-secreting macroadenoma by MRI, which was taken before and after the surgery. A. About 30 mm sized macroadenoma displacing the enhanced pituitary gland cranially (arrows) before the first TSA (upper panel) and residual tumor (arrow heads) after the first TSA (lower panel). B. About 20 mm sized macroadenoma (arrows) at the floor of pituitary fossa before the second TSA (upper panel) and completely resected tumor after the second the TSA (lower panel). TSA, trans-sphenoidal surgery; TSH, thyroid stimulating hormone.
enm-26-160f1.tif
Fig. 2.
A high-power view of the pituitary adenoma. A. Tumor tissues show regular thin fibrous septa surrounding tumor cells and chromophobe adenoma (H&E stain, × 200). B-D. Immunohistochemical staining of the tumor cells was positive to TSH (B). and GH (C). and negative to PRL (D). (× 100). GH, growth hormone; RPL, prolactin; TSH, thyroid stimulating hormone.
enm-26-160f2.tif
Fig. 3.
Clinical course of the patient (changes in free T4 and TSH levels). MMI, methima-zole; POD, postoperative days; T4, thyroxine; TSA, trans-sphenoidal surgery; TSH, thyroid stimulating hormone
enm-26-160f3.tif
Table 1.
Results of 75 g glucose-GH suppression test
Basal 60 min 120 min
Glucose (mg/dL) 82 193 160
GH (ng/mL) 2.66 0.63 0.58

GH normal, 0-9.5 ng/mL. GH, growth hormone.

Table 2.
Result of combined pituitary stimulation test (Regular insulin 0.1 U/kg, TRH 400 µ g, LHRH 100 µ g IV)
Basal 30 min 60 min 90 min 120 min
Glucose (mg/dL) 83 34 46 59 80
GH (ng/mL) 1.98 9.31 10.87 9.99 5.6
TSH (µ IU/mL) 4.84 5.56 5.75 5.38 4.48
Prolactin (ng/mL) 9.32 45.64 50.13 61.5 32.64
Cortisol (µ g/dL) 3.64 7.42 18.40 20.09 22.67
ACTH (pg/mL) 3.21 184.50 155.20 114.80 39.57
LH (mIU/mL) 4.15 13.63 24.49 20.55 14.72
FSH (mIU/mL) 2.45 3.38 5.41 5.67 5.51

ACTH, adrenocorticotropic hormone; FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; LHRH, luteinizing hormone-releasing hormone; TRH, thyrotropin-releasing hormone; TSH, thyroid stimulating hormone.

TOOLS
Similar articles